Pelthos Therapeutics Inc. (PTHS): Revenue

Annual figures by period end, from SEC filings.

$16.80M

Year ended 2025-12-31

$43.30M

Trailing 12 months to 2026-06-30

2024-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$16.80M	n/a	2026-03-19, From 2025-01-01
2024-12-31	$0	n/a	2026-03-19, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$16.80M	n/a
Relay Therapeutics, Inc. (RLAY)	2025-12-31	$15.36M	+53.4%
LENZ Therapeutics, Inc. (LENZ)	2025-12-31	$19.09M	n/a
Lineage Cell Therapeutics, Inc. (LCTX)	2025-12-31	$14.56M	+53.2%
Alector, Inc. (ALEC)	2025-12-31	$21.05M	-79.1%
Metagenomi Therapeutics, Inc. (MGX)	2025-12-31	$25.21M	-51.8%
Caribou Biosciences, Inc. (CRBU)	2025-12-31	$11.16M	+11.7%
TScan Therapeutics, Inc. (TCRX)	2025-12-31	$10.32M	+266.7%
Alpha Cognition Inc. (ACOG)	2025-12-31	$10.22M	n/a

Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗